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Abstract
Background: In Honduras, chloroquine and primaquine are recommended and still appear to be effective for
treatment of Plasmodium falciparum and Plasmodium vivax malaria. The aim of this study was to determine the
proportion of resistance associated genetic polymorphisms in P. falciparum and P. vivax collected in Honduras.
Methods: Blood samples were collected from patients seeking medical attention at the Hospital Escuela in Tegucigalpa
from 2004 to 2006 as well as three regional hospitals, two health centres and one regional laboratory during 2009.
Single nucleotide polymorphisms in P. falciparum chloroquine resistance transporter (pfcrt), multidrug resistance 1
(pfmdr1), dihydrofolate reductase (pfdhfr) and dihydropteroate synthase (pfdhps) genes and in P. vivax multidrug
resistance 1 (pvmdr1) and dihydrofolate reductase (pvdhfr) genes were detected using PCR based methods.
Results: Thirty seven P. falciparum and 64 P. vivax samples were collected. All P. falciparum infections acquired in
Honduras carried pfcrt, pfmdr1, pfdhps and pfdhfr alleles associated with chloroquine, amodiaquine and sulphadoxine-
pyrimethamine sensitivity only. One patient with parasites acquired on a Pacific Island had pfcrt 76 T and pfmdr1 86Y
alleles. That patient and a patient infected in West Africa had pfdhfr 51I, 59 R and 108 N alleles. Pvmdr1 976 F was found
in 7/37 and two copies of pvmdr1 were found in 1/37 samples. Pvdhfr 57 L + 58 R was observed in 2/57 samples.
Conclusion: The results indicate that P. falciparum from Honduras remain sensitive to chloroquine and
sulphadoxine-pyrimethamine. This suggests that chloroquine and sulphadoxine-pyrimethamine should be
efficacious for treatment of uncomplicated P. falciparum malaria, supporting current national treatment guidelines.
However, genetic polymorphisms associated with chloroquine and sulphadoxine-pyrimethamine tolerance were
detected in local P. vivax and imported P. falciparum infections. Continuous monitoring of the prevalence of drug
resistant/tolerant P. falciparum and P. vivax is therefore essential also in Honduras.
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Background
In Honduras chloroquine is recommended for treatment
of uncomplicated Plasmodium falciparum and Plasmo-
dium vivax infection. In addition primaquine is used for
treatment of P. falciparum gametocytes and P. vivax hyp-
nozoites [1,2]. These drugs are believed to remain effective
despite being used for six decades and despite the spread
of chloroquine resistance across most of the rest of the
world. However, there is lack of clinical trials as well as in
vitro studies and the proportions of resistance associated
genetic polymorphisms have not been determined in Hon-
duras or other Mesoamerican countries [3].
There are several genetic polymorphisms described in
P. falciparum and P. vivax that can provide reliable data
about the prevalence of drug resistance. The most rele-
vant polymorphisms are presented below. The 76 T allele
in the chloroquine resistance transporter gene (pfcrt)i s
* Correspondence: irina.jovel@ki.se
1Malaria Research Laboratory, Infectious Diseases Unit, Department of
Medicine, Karolinska University Hospital/Karolinska Institutet, Retzius väg 10,
171 77 Stockholm, Sweden
Full list of author information is available at the end of the article
Jovel et al. Malaria Journal 2011, 10:376
http://www.malariajournal.com/content/10/1/376
© 2011 Jovel et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
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failure [4-6]. The 86Y allele of the multidrug resistance
gene 1 (pfmdr1) has been linked with chloroquine and
amodiaquine resistance and increased chloroquine inhi-
bitory concentrations in P. falciparum with pfcrt 76 T
[7]. The pfcrt 76 K and pfmdr1 86 N alleles have been
associated with lumefantrine tolerance and higher lume-
fantrine IC50 values [8-10]. Amplifications of pfmdr1
have been associated with mefloquine resistance, lume-
fantrine tolerance and reduced sensitivity to artesunate
[11-13]. The triple dihydrofolate reductase (pfdhfr) haplo-
type N51I/C59R/S108N has been associated with sulpha-
doxine-pyrimethamine (SP) treatment failure and when
dihydropteroate synthase (pfdhps) SNPs G437A and
K540E are added, highly resistant P. falciparum are gen-
erated [14-18].
In P. vivax, the multidrug resistance gene 1 (pvmdr1)
976 F allele has been associated with reduced susceptibility
to chloroquine and increased susceptibility to mefloquine
and artesunate. However, amplifications of pvmdr1 have
been associated with reduced susceptibility to mefloquine
and artesunate [18-20]. Twenty single nucleotide poly-
morphisms have been described in P. vivax dihydrofolate
reductase (pvdhfr) including F57L, S58R, T61M and
S117N/T that correspond to codons 50, 51, 59 and 108 in
pfdhfr, respectively [21-24]. Pvdhfr S58R and S117N result
in decreased binding of pyrimethamine [25] and quadruple
(F57L, S58R, S117N and I173L) resistance associated SNPs
have been associated with SP treatment failure [21-23].
The aim of the study was to determine the proportion of
resistance associated genetic polymorphisms in P. falci-
parum and P. vivax field samples collected in Honduras.
Methods
Study setting, participants and ethics
In Honduras malaria transmission is seasonal and in 2010
there were 9,078 reported malaria cases. Plasmodium
vivax mono-infection accounted for 88% and 12% were
due to Plasmodium falciparum mono-infection and mixed
P. vivax and P. falciparum infections. The country is
divided into 20 health regions and there are 1,743 health
facilities [2]. Samples were collected from patients that
sought medical attention at the Hospital Escuela that is a
teaching hospital in Distrito Central-Tegucigalpa, the
regional hospitals in Trujillo, La Ceiba and Juticalpa, two
primary health centres in Puerto Lempira and Iriona and
one regional laboratory in Juticalpa. Samples were col-
lected at Hospital Escuela between 2004 and 2006 and
during 2009 at all other sites. The locations of all sites are
shown in Figure 1. At the Hospital Escuela sample collec-
tion was considered to be part of routine malaria surveil-
lance and did not involve additional sampling or collection
of patient data. At the other health facilities patients who
sought medical attention and were diagnosed with malaria
were invited to participate in the study after written
informed consent. The study was approved by the ethical
review committee of Cardio Pulmonary National Institute
in Tegucigalpa, Honduras. The molecular analyses were
approved by the Stockholm regional ethics board (refer-
ence number 2011/832-32/2).
Sample collection and microscopy
As part of routine practice, 3 ml of blood were collected in
EDTA tubes by venepuncture at the Hospital Escuela.
Thick and thin smears were made and stained using
Giemsa. Slides were viewed under X100 magnification.
Trained laboratory technician examined at least 100
microscopy fields before considering a sample negative.
When P. falciparum or P. vivax were identified approxi-
mately 100 μL of blood was collected on a filter paper
(Schleicher & Schuell 903) that was dried, placed inside a
small plastic bag and stored at room temperature. At the
other health units the samples were generally collected in
the same way but occasionally capillary samples were
obtained by finger puncture. Microscopy was quality con-
trolled at the National Malaria Laboratory were microsco-
pists routinely re-examine all positive and approximately
10% of negative slides.
Sample storage, DNA extraction and amplification
DNA was extracted from the filter papers using an ABI
Prism
® 6100 Nucleic Acid Prep Station (Applied Biosys-
tems, Fresno, CA) according to the manufacturer’s
instructions with minor modifications [26]. Extracted
DNA was stored at-20°C.
Previously described multiplex PCR-RFLP (restriction
fragment length polymorphism) methods were used to
identify the following SNPs; pfcrt K76T, pfmdr1 N86Y,
pfdhfr N51I, C59R, N108T/S and pfdhps G437A and
K540E [27]. Pfcrt 72-76 haplotypes were identified by PCR
amplification followed by sequencing [28]. Previously
described nested PCRs were used to amplify codons 917-
1118 of pvmdr1 and codons 1-238 of pvdhfr [19,29].
Pvmdr1 and pvdhfr SNPs were then identified by sequen-
cing. The Sequencher ™ software version 4.6 (Gene
Codes Corporation, Ann Arbor, MI) was used for sequen-
cing analysis. The P. falciparum 3D7 clone sequence
obtained from NCBI database (pfcrt Gen-Bank Accession
no. NC_004328) was used as reference for pfcrt.F o r
pvdhfr the P. vivax ARI/Pakistan isolate sequence (Gen-
Bank accession no. X98123) and for pvmdr1 the P. vivax
Sal-1 isolate sequence (Gen-Bank accession no.
AY618622) were used as references. PCR and restriction
products were resolved on 2% agarose gels (Amresco,
Solon, OH). All gels were stained with ethidium bromide
and visualized under UV transillumination (GelDoc
®,
Biorad, Hercules, Ca, USA). PCR products were purified
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Korea).
Pfmdr1 and pvmdr1 copy numbers were determined
using real time PCR (ABI Prism
® 7000 Sequence Detec-
tion System) as previously described [12,30]. All samples
were run in triplicate. For pfmdr1 3D7, D10 and K1 clones
were used as single copy calibrators and FCB and Dd2
were multiple copy controls. Pvmdr1 single and double
copy calibrators were created by the insertion of pvmdr1
nucleotides 2751-3354 and pvbtubulin nucleotides 860-
1056 in the pCR2.1 vector using the TOPO TA-cloning
kit (Invitrogen, Carlsbad, CA) at 1:1 and 2:1 proportions,
respectively. The sample copy numbers were calculated
using a comparative threshold method (ΔΔCt). Copy num-
ber > 1.6 was defined as a duplication of the aforemen-
tioned genes. Assays were repeated if the following results
were obtained: copy number 1.3-1.6 or Ct value > 35 or
standard deviation value > 0.5.
Power calculation and statistical analyses
This was an exploratory study and a power calculation of
sample size was therefore not done. Data were entered,
validated and analysed on Microsoft Excel 2003. For both
species allele proportions were calculated by dividing the
number of samples with a certain allele by the number of
samples with an identifiable allele at that position. Thus
mixed infections contributed to the proportion of both
alleles.
Results
Sample collection
At the Hospital Escuela blood samples were collected from
29 patients with Plasmodium falciparum mono-infection,
15 patients with Plasmodium vivax mono-infection and
four patients with mixed infections. Two patients with
P. falciparum mono-infection were assumed to have con-
tracted their infections on a Pacific island and in West
Africa based on their respective travel history. At the
other laboratories and health centres samples were col-
lected from four patients with P. falciparum and 45
patients with P. vivax mono-infections. Further details are
shown in Table 1.
Polymorphisms in Plasmodium falciparum
Pfcrt K76T, pfmdr1 N86Y, pfmdr1 copy numbers, pfdhfr
SNPs and pfdhps SNPs were successfully identified in 32/
37 (91%) of samples. Allele proportions are presented in
Table 2. All P. falciparum from Honduras (n = 30) had
Figure 1 Distribution of malaria in the 128 municipalities in Honduras. Annual Parasite Incidence per 1,000 habitants. Samples were
collected in (1) Distrito Central-Tegucigalpa, (2) Juticalpa, (3) Puerto Lempira, (4) Iriona, (5) Trujillo, (6) La Ceiba. The figure has been modified
from [2] to provide more detail.
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became infected with P. falciparum in West Africa had
the pfcrt 72-76 CVMNK haplotype and the patient
infected on a Pacific island had the SVMNT haplotype.
No other pfcrt SNPs were found in any of the sequenced
fragments. Both imported cases had the pfmdr1 86Y
allele and pfdhfr triple mutation 51I + 59 R + 108 N. One
pfmdr1 copy was found in all samples.
Polymorphisms in Plasmodium vivax
PCR amplifications of pvmdr1 were successful in 64/64
samples. Following sequencing, codon 976 was identified
in 41 samples and codon 1076 in 37 samples. Proportions
of the alleles are shown in Table 3. The double mutation
976 F + 1076 L was observed in 4/37 (11%) samples. No
other pvmdr1 SNPs were found in the sequenced frag-
ments. Pvmdr1 gene copy numbers were successfully
quantified in 61/64 samples. Two pvmdr1 gene copies
were found in one sample and one sample repeatedly had
an indeterminate 1.5 copies. These results were verified
by performing the real time PCR 5 times for these sam-
ples. The pvmdr1 gene amplification was found in
P. vivax that had the 976Y.
Pvdhfr was successfully amplified in 59/64 (92%) sam-
ples and sequencing was successful in 57 samples. Allele
Proportions are presented in Table 4. The 57 L + 58 R
double mutation was seen in 2/57 (3%) samples. Synon-
y m o u sS N P si nc o d o n6 9( T A T® TAC) were found in
13/57 (22%) samples. Two novel SNPs in codons 39
(CTG ® TTG) and 85 (TCA ® TCC) were observed in
2 (3%) and 3 (5%) samples, respectively. A repetition
(ACA AGC GGT GGT GAC AAC) between amino acids
103 and 104 of pvdhfr was found in 5/57 (9%) of the
samples.
Discussion
This is the first report on molecular markers of drug
resistance from Honduras and indeed from Mesoamerica
[3]. Finding no SNPs associated with CQ or SP resistance
in Plasmodium falciparum from Honduras indicates that
P. falciparum of Honduran origin remain CQ and SP
sensitive. The results are in line with the continued effi-
cacy of CQ seen in previous in vitro (1980) and in vivo
(1980 and 1998-2000) studies [31,32]. This study thus
indicates that the use of CQ in combination with prima-
quine for treatment of uncomplicated P. falciparum
malaria and SP when CQ fails as recommended in the
national treatment guidelines should be efficacious [1].
However, 2/2 patients with imported malaria had ≥ 3
SNPs associated with SP resistance suggesting that SP is
not optimal for treating infections from regions outside
Mesoamerica as is also recommended in the national
treatment guidelines.
The results indicate that pfcrt 76 K, pfmdr1 86 N and
SNPs in pfdhfr and pfdhps associated with SP sensitivity
are fixed in Honduras. This suggests that P. falciparum in
Honduras are less susceptible to lumefantrine and possibly
mefloquine compared to areas where the dominant SNPs
are pfcrt 76 T and pfmdr1 86Y [8-10,33]. Should Honduras
wish to introduce an artemisinin-based treatment, combi-
nations containing amodiaquine or SP might, from the
point of view of drug sensitivity, be preferred over combi-
nations containing lumefantrine or mefloquine.
The high proportion of patients with P. falciparum com-
pared to Plasmodium vivax infection at the Hospital
Escuela was most probably due patients with P. falciparum
being referred there. The two patients with imported
malaria had according to their history of travel contracted
P. falciparum on a Pacific island and in West Africa. Find-
ing the pfcrt 72-76 SVMNT and CVMNK haplotypes is
consistent with their respective travel histories suggesting
that the resistance associated SNPs found were truly
imported [34,35]. These two patients highlight the risk of
Table 1 Origin of samples
Municipalities P. falciparum P. vivax Mix inf
Distrito Central- 29 15 4
Tegucigalpa
Juticalpa 26
Puerto Lempira 23
Iriona 2
Trujillo 8
La Ceiba 8
*Two patients contracted malaria elsewhere: A tourist who was admitted one
week after arriving in Honduras from the Pacific island region where he had
been travelling. A pilot who was admitted the day he came to Honduras after
working and visiting Equatorial Guinea, Ghana and Cameron during the
previous three months.
Table 2 Single nucleotide polymorphisms and amplifications in pfcrt, pfmdr1, pfdhfr and pfdhps
Origin pfcrt pfmdr1 Pfdhfr Pfdhps Number (Proportion %)
76 86 Copy Number 51 59 108 437 540
Honduras K N 1 N C S A K 30 (94)
§
Pacific T Y 1 IR N A K 1 (3)
Africa K Y 1 IR N G /A K 1 (3)
*Resistance associated alleles are shown in bold
§All infections were acquired in Honduras
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ing this it is worth noting that malaria is often diagnosed
clinically in Honduras and that it is then treated presump-
tively with primaquine (0,25 mg/kg) for 5 days in addition
to CQ. Primaquine reduces the gametocytes carriage time
thus reducing transmission and it is certainly possible that
this has contributed to stop resistant P. falciparum from
becoming established [36,37].
CQ resistant P. vivax has been reported from several
Asian and South American countries including Brazil, but
not French Guiana [38]. In Southeast Asia the pvmdr1 976
F allele has been associated with reduced susceptibility to
CQ [19] and in Brazil it was found in 100% of samples
(n = 28) whilst it was not found in French Guiana (n = 5)
[39,40]. Finding the pvmdr1 976 F allele in 7/41 (17%)
P. vivax might thus indicate a degree of CQ tolerance but
probably not resistance in Honduras [18,19,41]. In line
with this, an in vivo evaluation conducted in Honduras
between 1998 and 2000 found that 73/73 P. vivax infec-
tions were successfully treated with CQ and primaquine
[32]. Finding two copies of pvmdr1 in 1/61 samples should
be interpreted with caution as neither mefloquine nor
artesunate are commonly used in Honduras [20]. It may
however suggest the natural occurrence of this genetic
change in Honduras. The prevalence of pvmdr1 1076 L
varies considerably across the world and although an asso-
ciation with CQ resistance has been proposed none has
yet been found [18,19,39-42]. The proportion in Honduras
(4/37) is similar to that found in Brazil (4/28). In the
pvmdr1 fragment amplified for this study one synonymous
and nine non-synonymous SNPs have been reported
worldwide. Five of these SNPs have been reported from
South America in studies including nine patients whereas
only one was found in this study [43,44].
Double (57 L + 117 N), triple (57 L + 58R + 117 N)
and quadruple (57 L + 58R + 61 M + 117 T) pvdhfr
mutations have been associated with SP resistant
P. vivax [21,24,34]. In this study 2/57 samples had the
double 57 L + 58 R SNPs that have previously been
described in similar proportions in Asia but not in
South America [21,24,29,45-48]. These SNPs may sug-
gest a degree of tolerance but probably not resistance to
SP. It is thus probable that SP should be efficacious for
the treatment of P. vivax in Honduras [49]. However,
the efficacy of SP for the treatment of P. vivax has not
been assessed in Mesoamerica [3]. Furthermore, finding
the double mutation despite a probably low consump-
tion of SP suggests that resistance might develop rapidly
if SP usage increases. A possible explanation for the
occurrence of 57 L and 58 R despite the low use of SP
for malaria might be that trimethoprim/sulfamethoxa-
zole is the first line drug for treatment of acute respira-
tory tract infections in Honduras [50]. Two novel
synonymous SNPs at codons 39 and 85, a previously
described synonymous SNP at codon 69 and an inser-
tion, were also found in pvdhfr. The proportion of SNP
69 (13/57) found in this study was considerably lower
than that (77/90) reported from French Guiana [44].
Conclusion
Only SNPs linked to CQ or SP sensitivity were found in
Plasmodium falciparum originating in Honduras indicat-
i n gt h a tC Qa n dS Ps h o u l dr e main efficacious. Genetic
polymorphisms associated with CQ and SP tolerance
were found in eight (13%) and two (3%) Plasmodium
vivax samples, respectively, suggesting a degree of toler-
ance. CQ and SP resistance associated SNPs were found
in patients that contracted P. falciparum overseas high-
lighting the risk of importing drug resistance to Hon-
duras. Continuous monitoring of the prevalence of drug
resistant/tolerant P. falciparum and P. vivax in Honduras
is, therefore, essential.
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